Observed Signal · Sep 23, 2026 · Funding · Source: techcrunch · Impact: 1/5 · Sentiment: Positive

Enveda raises $311M for AI drug discovery

Executive Signal Summary

Enveda, an AI-driven biotech startup focused on discovering drugs from natural sources, has raised $311 million in a Series E funding round at a $2 billion valuation. The round was led by Catalio Capital Management, with participation from Iconiq and others, doubling the company's valuation from 12 months ago. Enveda, founded in 2019 by Viswa Colluru, uses AI to accelerate the discovery of drugs from plants and microbes. The startup is currently advancing several drug candidates into clinical trials, including treatments for severe skin conditions and a drug designed to maintain weight loss after discontinuation of GLP-1s. This funding will support further clinical development.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Not relevant to AdTech/MarTech/Advertising/AI industry.

SIGNAL RADAR

Track ICONIQ Signals & Market Shifts in Real-Time

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • Enveda raised $311 million in Series E funding at a $2 billion valuation.
  • Catalio Capital Management led the round, with participation from Iconiq and others.
  • The new valuation doubles Enveda's valuation from 12 months ago.
  • Enveda uses AI to discover drugs from natural sources like plants and microbes.
  • The company is testing drugs for skin conditions and weight loss maintenance post-GLP-1.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: techcrunch•Published: Sep 23, 2026
Original Coverage Title: “Enveda secures $311M to bring more nature-derived AI drugs into clinical trials”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

Large Language Models (LLM) & AIAug 26, 2026

Veeda raises $90M seed for multi-modal world models

A new AI startup called Veeda, founded by three former Nvidia employees including noted AI researcher Sanja Fidler, announced a $90 million seed funding round led by Khosla Ventures and Radical Ventures. Veeda plans to build multi-modal world models aimed at embodied intelligence and robotics. The story was first reported by The Logic; the article situates this round amid growing investor interest in world-model approaches and mentions potential acquisitions and activity from larger AI companies such as Anthropic.

Read assessment
FundingNov 10, 2026

Proximal Ventures Raises $27.5M for AI Drug Development Fund

Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.

Read assessment
AISep 22, 2026

Biolevate raises €30M Series A for life sciences AI

Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for ICONIQ & competitors in your briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime